Related Experiment Video
Updated: Jul 5, 2026

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse
Published on: April 7, 2014
The effect of topical bevacizumab on corneal neovascularization
Sang Woo Kim1, Byung Jin Ha, Eung Kweon Kim
1Corneal Dystrophy Research Institute, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose:
To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.
Design:
Prospective, nonrandomized, masked observational case series.
Participants:
Ten eyes of 7 patients with corneal NV.
Methods:
Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.
Main Outcome Measures:
Corneal NV and changes in ophthalmic evaluations.
Results:
Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
Conclusions:
Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Cytotoxic Edema: Pathophysiology
